GLP-1R Agonist Crystal Forms for Stable Drug Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-1 receptor agonists face challenges in developing solid forms that enable easy isolation, purification, large-scale manufacture, and stability during storage and administration, while maintaining solubility and bioavailability.
Innovation Solution
The development of four novel crystalline forms of Compound A free acid, including Form I, Form II, Form III, and Form IV, which are characterized by specific X-ray powder diffraction patterns and thermal properties, providing stability and solubility suitable for pharmaceutical formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a solid form is developed for easy isolation and purification, then manufacturing ease is improved, but solubility and bioavailability may be reduced
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline forms (Form I, Form II, Form III, Form IV) with different physical and chemical parameters. Each crystalline form has distinct X-ray powder diffraction patterns, melting points, and solubility characteristics. This allows selection of the optimal crystalline form that balances ease of manufacture with adequate solubility and bioavailability for the specific pharmaceutical application.
2Productivity
If a solid form is developed for large-scale manufacture, then productivity is improved, but stability during storage may be compromised
Solution Approach 1:
The patent utilizes phase transitions by characterizing and selecting specific crystalline forms with defined melting points and thermal properties. Each crystalline form exhibits distinct thermal behavior and phase transition characteristics that ensure stability during storage and handling. The selected crystalline forms maintain their structural integrity under various storage conditions while remaining suitable for large-scale manufacturing processes.
3Reliability
If a solid form is developed for extended storage with minimal water absorption, then reliability is improved, but manufacturing complexity may increase
Solution Approach 1:
The patent applies local quality by optimizing specific properties of each crystalline form to achieve minimal water absorption and enhanced storage stability. Each crystalline form has been characterized for its hygroscopic properties, with selected forms demonstrating superior resistance to water absorption. This localized optimization of water resistance allows for extended storage without requiring complex manufacturing or packaging modifications.
Data Source
AI summary
Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.